Skip to main content
STRIDES PHARMA SCIENCE LIMITED logo

STRIDES PHARMA SCIENCE LIMITED — Investor Relations & Filings

Ticker · STAR ISIN · INE939A01011 LEI · 335800WHFYXUCHR9DD10 BSE.NS Manufacturing
Open in API
Filings indexed 1,189 across all filing types
Latest filing 2026-02-05 Regulatory Filings
Country IN India
Listing BSE.NS STAR

About STRIDES PHARMA SCIENCE LIMITED

https://www.strides.com

Strides Pharma Science Limited is a global pharmaceutical organization focused on the development and manufacture of IP-led niche finished dosage formulations. The company’s product portfolio encompasses a wide range of therapeutic areas, specializing in complex oral solids, softgel capsules, topicals, and liquids. It maintains a significant presence in highly regulated markets, including the United States, Europe, and Australia, while also serving institutional and emerging markets. The company operates multiple manufacturing facilities globally, many of which are approved by major international regulatory agencies such as the USFDA. Strides emphasizes research and development to drive innovation in specialized delivery systems and difficult-to-manufacture products, positioning itself as a key player in the global generic pharmaceutical landscape.

Recent filings

Filing Released Lang Actions
Press Release
Regulatory Filings Classification · 95% confidence The document is a press release dated February 5, 2026, announcing that Strides Pharma Inc. received the USFDA closure report (Establishment Inspection Report - EIR) for its formulations facility. It describes the inspection details and the outcome but does not contain any financial data, regulatory filings, or detailed reports. The document is a communication to stock exchanges and the public about a regulatory inspection result, typical of a press release. It is not an annual report, audit report, earnings release, or any other detailed financial or governance report. Therefore, the best fitting category is a Regulatory Filing (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other categories.
2026-02-05 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice informing stock exchanges about the schedule of an analyst/institutional investor meeting. It references a previously uploaded earnings presentation for Q3 FY26 but does not contain any financial data or detailed report itself. The document is an announcement of a meeting and related schedule, not the earnings release or presentation itself. The length is only 1759 characters, indicating it is a brief communication. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and disclosure under SEBI regulations.
2026-02-04 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a detailed transcript of an earnings call for the quarter and nine months ended December 31, 2025, for Strides Pharma Science Limited. It includes management commentary on financial results, business performance, strategic priorities, and outlook. The text explicitly mentions it is a transcript of the earnings call, with multiple speakers including the CEO, CFO, and investor relations consultant. The content includes financial highlights, operational metrics, and forward-looking statements typical of earnings call transcripts. There is no indication that this is a brief announcement or a report publication notice; rather, it is the full transcript of the call. Therefore, the document fits the category of a Call Transcript (CT).
2026-02-03 English
Copy of Newspaper Publication
Report Publication Announcement Classification · 95% confidence The document is a letter addressed to stock exchanges (BSE and NSE) dated January 31, 2026, from Strides Pharma Science Limited. It announces the publication of un-audited financial results for the quarter and nine months ended December 31, 2025, in newspapers and on the company's website. The document includes a newspaper advertisement extract of these financial results. The content is a notification of the publication of financial results rather than the full financial report itself. The document length is 5662 characters, which is relatively short and consistent with an announcement rather than a full interim or quarterly report. Therefore, according to the "Menu vs Meal" rule, this document should be classified as a Report Publication Announcement (RPA) rather than an Interim/Quarterly Report (IR) or Earnings Release (ER).
2026-01-31 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short letter addressed to stock exchanges informing about the availability of the audio recording of an earnings call discussing unaudited financial results for the quarter and nine months ended December 31, 2025. It references the earnings call but does not contain the financial results or detailed transcript itself. The document length is only 1512 characters, which is quite short and fits the pattern of an announcement rather than the full earnings release or call transcript. According to the rules, announcements about availability of earnings call recordings are best classified as Regulatory Filings (RNS) since they do not contain the actual financial data or transcript but are regulatory disclosures about such events.
2026-01-30 English
General Updates
Investor Presentation Classification · 95% confidence The document is titled 'Earnings Presentation for the quarter and nine months ended December 31, 2025' and is dated January 30, 2026. It contains detailed financial performance data including revenue, EBITDA, PAT, EPS, and segment-wise analysis for Q3FY26 and 9MFY26. The document includes forward-looking statements, operational highlights, market commentary, and business outlook. It is a presentation format with charts and tables summarizing quarterly and nine-month financial results. The document is not a brief announcement but a detailed presentation intended for investors and stakeholders. Therefore, it fits the category of an Investor Presentation (IP) rather than an Earnings Release (ER) which would be a shorter announcement of key financial results. The length (15,000 characters) and content confirm it is a full presentation document rather than a simple announcement or regulatory filing. Hence, the correct classification is Investor Presentation (IP).
2026-01-30 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.